Study identifier:D7040C00001
ClinicalTrials.gov identifier:NCT06795022
EudraCT identifier:N/A
CTIS identifier:N/A
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1)
Hepatocellular Carcinoma
Phase 1/2
No
AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy)
All
304
Interventional
18 Years - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jan 2025 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Module 1: AZD9793 Intravenous (IV) monotherapy Module 1: AZD9793 Intravenous (IV) monotherapy | Drug: AZD9793 Intravenous (IV) monotherapy T cell-engaging antibody that targets GPC3 on tumour cells |
Experimental: Module 2: AZD9793 Subcutaneous (SC) monotherapy Module 2: AZD9793 Subcutaneous (SC) monotherapy | Drug: AZD9793 Subcutaneous (SC) monotherapy) T cell-engaging antibody that targets GPC3 on tumour cells |